financetom
Business
financetom
/
Business
/
Gilead Sciences Insider Sold Shares Worth $277,575, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Gilead Sciences Insider Sold Shares Worth $277,575, According to a Recent SEC Filing
Jul 16, 2025 3:19 PM

05:47 PM EDT, 07/16/2025 (MT Newswires) -- Andrew D Dickinson, Chief Financial Officer, on July 15, 2025, sold 2,500 shares in Gilead Sciences ( GILD ) for $277,575. Following the Form 4 filing with the SEC, Dickinson has control over a total of 162,610 common shares of the company, with 162,610 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/882095/000112760225019286/xslF345X05/form4.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Vecima Networks Terminates Agreement to Buy Casa Systems' Cable Business Assets
Vecima Networks Terminates Agreement to Buy Casa Systems' Cable Business Assets
Jun 10, 2024
06:17 AM EDT, 06/10/2024 (MT Newswires) -- Vecima Networks ( VNWTF ) over the weekend said it terminated an agreement to buy Casa Systems' its cable business assets. At a June 4 hearing, the U.S. Bankruptcy Court for the District of Delaware approved the sale of the cable business assets to a different bidder. The agreement between Vecima and Casa...
Moderna COVID/flu combo vaccine superior to separate shots in trial
Moderna COVID/flu combo vaccine superior to separate shots in trial
Jun 10, 2024
June 10 (Reuters) - Moderna ( MRNA ) said on Monday its combination vaccine to protect against both COVID-19 and influenza generated a stronger immune response in adults aged 50 and over when compared to separate shots against the viruses in a late-stage trial. In the study, the combination using messenger RNA technology generated greater antibodies than currently marketed traditional...
Oculis Sees Favorable Topline Results in Study of Potential Dye-Eye Disease Treatment
Oculis Sees Favorable Topline Results in Study of Potential Dye-Eye Disease Treatment
Jun 10, 2024
06:44 AM EDT, 06/10/2024 (MT Newswires) -- Oculis Holding (OCS) said Monday it had detected favorable topline results from a phase 2b trial of licaminlimab for the treatment of patients with dry-eye disease. The 122-patient study showed treatment effects favoring licaminlimab in multiple sign endpoints accepted by the US Food and Drug Administration. ...
US Equity Investors to Focus on Outlook for Fed's Policy Path Following Latest Read on Inflation This Week
US Equity Investors to Focus on Outlook for Fed's Policy Path Following Latest Read on Inflation This Week
Jun 10, 2024
06:28 AM EDT, 06/10/2024 (MT Newswires) -- US equity investors will look out for the June Federal Reserve meeting and consumer price inflation data this week to assess the direction of interest rates and the impact of evolving monetary policy on the technology sector gains. * CPI for May arrives just hours ahead of Wednesday's policy announcement from the Federal...
Copyright 2023-2026 - www.financetom.com All Rights Reserved